# Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

Source: https://onco.cc/trials/nct05261399/  
OnCo record `nct05261399` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Savolitinib, Osimertinib, Pemetrexed, Cisplatin and Carboplatin in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment is a phase 3 interventional study registered as NCT05261399 by AstraZeneca, with 341 participants enrolled, started 2022-08-03 and due to reach its primary completion in 2026-07-06. Interventions recorded: Savolitinib, Osimertinib, Pemetrexed, Cisplatin and Carboplatin.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05261399
- Phase: 3
- Setting: A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).
- Sponsor: AstraZeneca
- Enrolled: 341

## Sources

- ClinicalTrials.gov NCT05261399: https://clinicaltrials.gov/study/NCT05261399

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [Savolitinib](https://onco.cc/drugs/savolitinib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct05261399.json